No risk of drug-associated liver injury with α 1-adrenoreceptor blocking agents in men with BPH: Results from an observational study using the GPRD

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 2, 2005, Pages 75-80

  Clifford, Gary M ^a   Logie, John ^a   Farmer, Richard D T ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

1 blockers; Adverse events; Benign prostatic hyperplasia; Case control study; Cohort study; Liver injury

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; HUMAN; INCIDENCE; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; UNITED KINGDOM; URINARY TRACT OBSTRUCTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; COHORT STUDIES; DATABASES, FACTUAL; HEPATITIS, TOXIC; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 13844296717     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.973     Document Type: Article

References (22)

1. Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 2000; 38: 2-19.
2. 1 -adrenoceptor subtype-specific blockade. Br J Urol 1998; 81(Suppl. 1): 34-47.
3. Rittmaster RS, Stoner E, Thompson DL, Nance D, Lasseter KC. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 1989; 10: 259-262.
4. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297-307.
5. 1-adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546-551.
6. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995; 288: 201-207.
7. 1A subtype. Eur J Pharmacol 1995; 289:81-86.
8. Lepor H. Long-tenn efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995; 45: 406-413.
9. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. Br J Urol 1993; 72: 615-620.
10. Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466-470.
11. Shakir S, Pearce G, Mann RD. Finasteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription- event monitoring data. BJU Int 2001; 87: 789-796.
12. Lukacs B, Grange JC, Comet D. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. Urology 2000; 55: 540-546.
13. Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol 1997; 157: 525-530.
14. Lukacs B, Blondin P, MacCarthy C, Du BB, Grippon P, Lassale C. Safety profile of 3 months' therapy with alfuzosin in 13 389 patients suffering from benign prostatic hypertrophy. Eur Urol 1996; 29 29-35.
15. 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29: 145-154.
16. Clifford GM, Logie J, Farmer RD. How do symptoms indicative of BPH progress in real life practice? The UK experience. Eur Urol 2000; 38 (Suppl. 1): 48-53.
17. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302: 766-768.
18. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999; 54: 413-419.
19. Nazareth I, King M, Haines A, Rangel L, Myers S. Accuracy of diagnosis of psychosis on general practice computer system. Br Med J 1993; 307: 32-34.
20. Van Staa T, Abenhaim L. The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Safe 1994; 3: 15-21.
21. STATA. Statistical Software, Release 5. 0. College Station, TX: Stata Corporation; 1997.
22. Joint Formulary Committee. British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2000.